ResMed Inc. $RMD Stake Cut by Danske Bank A S

Key Points

• Danske Bank A/S reduced its holding in ResMed by 33.7% in Q4, selling 54,410 shares and retaining 107,136 shares worth about $25.8 million.
• ResMed beat Q3 expectations with EPS of $2.86 (vs. $2.79 consensus) and revenue of $1.43 billion (up 10.8% YoY), leading several analysts to raise price targets and a consensus target of $286.18.
• The company declared a quarterly dividend of $0.60 per share (ex‑div May 14, payable June 18), while insiders have sold 21,023 shares (~$5.23M) in the past 90 days, including sales by the CEO and a director.

Danske Bank A S reduced its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 33.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,136 shares of the medical equipment provider's stock after selling 54,410 shares during the period. Danske Bank A S owned about 0.07% of ResMed worth $25,806,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of RMD. First Trust Advisors LP increased its position in ResMed by 285.1% in the 3rd quarter. First Trust Advisors LP now owns 445,198 shares of the medical equipment provider's stock worth $121,864,000 after purchasing an additional 329,588 shares during the last quarter. Marshall Wace LLP increased its position in ResMed by 2,373.1% in the 3rd quarter. Marshall Wace LLP now owns 310,987 shares of the medical equipment provider's stock worth $85,126,000 after purchasing an additional 298,412 shares during the last quarter. Nordea Investment Management AB increased its position in ResMed by 37.2% in the 4th quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider's stock worth $262,027,000 after purchasing an additional 294,124 shares during the last quarter. Vanguard Group Inc. increased its position in ResMed by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 19,040,440 shares of the medical equipment provider's stock worth $5,211,940,000 after purchasing an additional 293,515 shares during the last quarter. Finally, Giverny Capital Inc. acquired a new position in ResMed in the 3rd quarter worth about $64,441,000. 54.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction on Monday, February 9th. The shares were sold at an average price of $273.78, for a total value of $1,366,435.98. Following the completion of the transaction, the chief executive officer owned 466,223 shares of the company's stock, valued at approximately $127,642,532.94. The trade was a 1.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 21,023 shares of company stock valued at $5,230,857 in the last 90 days. 0.65% of the stock is owned by corporate insiders.

ResMed Price Performance

Shares of RMD stock opened at $205.17 on Friday. The stock has a 50 day moving average of $233.35 and a two-hundred day moving average of $246.50. The company has a current ratio of 3.06, a quick ratio of 2.32 and a debt-to-equity ratio of 0.06. ResMed Inc. has a 12 month low of $198.64 and a 12 month high of $293.81. The company has a market capitalization of $29.89 billion, a P/E ratio of 19.79, a P/E/G ratio of 1.35 and a beta of 0.85.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 EPS for the quarter, topping analysts' consensus estimates of $2.79 by $0.07. The company had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.42 billion. ResMed had a return on equity of 25.72% and a net margin of 27.44%.The company's quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the company earned $2.37 EPS. As a group, equities analysts expect that ResMed Inc. will post 11.07 EPS for the current year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 18th. Investors of record on Thursday, May 14th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Thursday, May 14th. ResMed's dividend payout ratio (DPR) is 23.74%.

Analysts Set New Price Targets

Several research analysts have weighed in on RMD shares. Evercore set a $255.00 target price on ResMed and gave the stock an "outperform" rating in a research report on Monday, April 13th. Royal Bank Of Canada increased their price objective on ResMed from $314.00 to $321.00 and gave the company an "outperform" rating in a report on Friday. JPMorgan Chase & Co. started coverage on ResMed in a report on Wednesday, April 15th. They set an "overweight" rating on the stock. Stifel Nicolaus increased their price objective on ResMed from $260.00 to $265.00 and gave the company a "hold" rating in a report on Friday, January 30th. Finally, Wall Street Zen lowered ResMed from a "buy" rating to a "hold" rating in a report on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $286.18.

Trending Headlines about ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q3 results beat and margin expansion — ResMed reported revenue up ~11% to ~$1.4B, EPS above consensus, GAAP/non‑GAAP gross margins expanded ~290 bps, strong operating cash flow and $262M returned to shareholders via buybacks/dividends. These fundamentals support longer‑term earnings growth and cash return potential. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
• Positive Sentiment: Analyst bullish move — Royal Bank of Canada raised its price target to $321 and kept an outperform rating, signaling confidence in ResMed’s growth runway (this raises a sizable upside case). Benzinga
• Positive Sentiment: Dividend maintained and scheduled — Board declared a $0.60 quarterly dividend (ex‑div May 14, payable June 18), modest yield but adds to shareholder returns alongside buybacks.
• Neutral Sentiment: New CFO named — CFO Brett Sandercock will retire and Aaron Bloomer is appointed successor. Management continuity reduces execution risk, though investors will watch cadence of financial reporting under new leadership. ResMed beats quarterly profit estimates, names new CFO
• Neutral Sentiment: Strategic commentary and acquisition talk — Earnings call highlighted continued revenue growth drivers and strategic M&A/portfolio moves; useful context for longer‑term thesis but not immediate catalysts. ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
• Negative Sentiment: Shares slipped after earnings despite the beat — Market reaction was negative post‑release, suggesting investors had higher expectations for guidance, cadence, or near‑term execution; volatility may continue as analysts digest details. RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Mixed analyst reaction — Wells Fargo cut its target to $227 and assigned an equal‑weight rating, reflecting concern about near‑term upside and contributing to selling pressure for investors focused on shorter horizons. Benzinga

ResMed Company Profile

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.